Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.

Van Karlyle MorrisAmir JazaeriShannon N WestinCurtis PettawaySolly GeorgeRyan W HueyMichaela GrinsfelderAaron ShaferBenny JohnsonDavid ViningMing GuoBryan FellmanMichael Frumovitz

Published in: The oncologist (2023)

The combination of MEDI0457 and durvalumab demonstrated acceptable safety and tolerability in patients with advanced HPV-16/18 cancers. The low ORR among patients with cervical cancer led to study discontinuation despite a clinically meaningful disease control rate.

Keyphrases

open label
squamous cell carcinoma
small cell lung cancer
high grade
randomized controlled trial
clinical trial
young adults
double blind